Results 171 to 180 of about 51,637 (256)

Further Insights Into Anticholinergic Action Informed by Japanese Anticholinergic Risk Scale

open access: yesGeriatrics &Gerontology International, Volume 26, Issue 1, January 2026.
ABSTRACT The increased anticholinergic burden caused by medications in older adults is one of the adverse drug reactions of particular concern, as it can exacerbate the onset of geriatric syndromes or induce cognitive dysfunction, and is also related to the issue of polypharmacy.
Masaki Mogi   +4 more
wiley   +1 more source

Myasthenia gravis and autoimmune overlap: Prognostic insight. [PDF]

open access: yesPLoS One
Oguz-Akarsu E   +6 more
europepmc   +1 more source

Recent Progress in Double Filtration Plasmapheresis

open access: yesHemodialysis International, Volume 30, Issue 1, Page 18-25, January 2026.
ABSTRACT Double‐filtration plasmapheresis is an advanced extracorporeal blood purification technique that selectively removes pathogenic macromolecules based on molecular weight. Unlike conventional plasma exchange, double‐filtration plasmapheresis uses a two‐step filtration process to retain beneficial plasma components such as albumin, while ...
Dan Li   +3 more
wiley   +1 more source

Open-label study of efgartigimod in seronegative myasthenia gravis. [PDF]

open access: yesTher Adv Neurol Disord
Khateb M   +8 more
europepmc   +1 more source

AIRE's Complex Role Beyond Promiscuous Gene Expression

open access: yesImmunological Reviews, Volume 337, Issue 1, January 2026.
ABSTRACT Central tolerance, established in the thymus, ensures T cells are nonreactive to self‐antigens while maintaining a functional immune repertoire. Medullary thymic epithelial cells (mTECs) and thymic dendritic cells (DCs) play a crucial role in this mechanism by orchestrating the selection and deletion of autoreactive thymocytes, a process ...
Pärt Peterson
wiley   +1 more source

Chimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug

open access: yesHLA, Volume 107, Issue 1, January 2026.
ABSTRACT Initially, chimeric antigen receptor (CAR) T‐cell therapy was developed to eliminate malignant B cells in haematological B‐cell malignancies by targeting CD19 and B‐cell maturation antigen. This approach achieved notable success, resulting in (malignant) B‐cell depletion and inducing clinical remission in cancer patients.
Hannah C. M. Schenk   +8 more
wiley   +1 more source

FcRn inhibitors for myasthenia gravis. [PDF]

open access: yesCochrane Database Syst Rev
White LM   +8 more
europepmc   +1 more source

Myasthenia gravis and Schmidt syndrome [PDF]

open access: bronze, 1988
J. K. McAlpine, J.E. Thomson
openalex   +1 more source

Home - About - Disclaimer - Privacy